BridgeBio Pharma and Affiliate QED Therapeutics Announce FDA Acceptance of New Drug Application for Infigratinib for the Treatment of Cholangiocarcinoma

Matt Turner
Patient Affordability

Matthew Durham
Omnidynamic Marketing

Liz Kane
Impactful Strategy

Frank Burrell
Scientific Storytelling

Paul Theisen
Patient Acquisition

Amy Giles
Increasing Engagement

Suma Ramadas, PhD
Medical Affairs

Daniel Sontupe
Market Access

David Linetsky
Point-of-Care Marketing

Brenda Snow
Authentic Patient Voice

Stacey Gandler
Brand Nourishment

Joey Cohen
Medication Adherence

Bud Bilanich
Success Coach

Pat Purcell
Meeting Engagement